MedPath

Continuous Sciatic Nerve Block vs Epidural Analgesia in Lower Limb Amputation for Postoperative Pain

Phase 3
Not yet recruiting
Conditions
Phantom Limb Pain
Pain, Chronic
Interventions
Drug: Continuous sciatic nerve block
Drug: Epidural catheter
Registration Number
NCT05608733
Lead Sponsor
Universidad de Antioquia
Brief Summary

Controlled clinical trial of two parallel groups, with random assignment 1:1, non-inferiority, blinded for the patient, for who administers the intervention and for who analyzes the data. 112 participants

Detailed Description

Controlled clinical trial of two parallel groups, with random assignment 1:1, non-inferiority, blinded for the patient, for who administers the intervention and for who analyzes the data. 112 participants Outcomes: Primary: Numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain) was used for pain assessments daily for 15 days and subsequently monthly until completing 3 months. Co-primary: Assessment of symptomatology related to phantom limb pain daily for 15 days POP and subsequently monthly until completing 3 months.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
112
Inclusion Criteria
  1. Age over 18 years
  2. Being scheduled for above or below knee amputation or for bone remodeling of lower limb amputees
  3. Acceptance of continuous regional analgesic technique as part of their multimodal analgesia
Exclusion Criteria
  1. Traumatic cause of amputation
  2. Allergy to local anesthetics
  3. Contraindication for epidural technique or continuous blocks
  4. Stage 5 kidney disease
  5. Concomitant use of aspirin and clopidogrel
  6. Pregnancy status

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Continuous sciatic nerve blockContinuous sciatic nerve blockContinuous sciatic catheter infusion of bupivacaine 0.1% (6-10 cc/h)
Epidural catheterEpidural catheterEpidural catheter infusion of bupivacaine 0.1% (4-6 cc/h) at level L3-L4
Primary Outcome Measures
NameTimeMethod
Posoperative Pain3 months

Pain score according to the daily NRS scale (Numeric Pain Rating Scale), Numeric Pain Rating Scale, for 15 days POP and subsequently monthly until completing 3 months. is scores from 0 to 10, 10 being the worst value.

Phantom Limp Pain3 months

For this qualitative dichotomous outcome, you will ask about symptomatology referring to phantom limb pain for 15 days POP and subsequently monthly until completing 3 months, It will be qualified as positive if it presents any neuropathic symptom.

Secondary Outcome Measures
NameTimeMethod
Incidence of nausea and vomiting POP36 hours

Incidence of nausea and vomiting POP in each group: the appearance of nausea or vomiting at 12, 24 and 36 h POP will be asked.

Phantom Limp Pain first Year1 year

Presence of phantom limb pain on a monthly basis until completing 12 month, The patient will be asked about the appearance of any painful sensation described as stabbing, shooting, electric shock, dull, tight pain and/or cramp in the anatomical site where the amputated limb would be, evaluating the presence or absence of the same (s). This will be questioned every day for 15 POPs days and monthly follow-up will continue via telephone until completing 3 months.

Opioid Consumption36 hours

the total consumption in mg of morphine or its equivalent at 12, 24 and 36 h POP will be evaluated.

Incidence of adverse effects1 year

any appearance of hematoma, hypotension (defined as SBP less than 90 mmHg or a 30% decrease in baseline MAP) or bradycardia (HR less than 60 bpm) is defined.

Days of hospital stayduring the time of hospitalization, on average 10 days

Days of hospital stay through study completion

Mortality1 year

Mortality in the first Year

Trial Locations

Locations (1)

Antioquia´s University

🇨🇴

Medellin, Colombia

© Copyright 2025. All Rights Reserved by MedPath